Literature DB >> 3312851

Symposium on antimicrobial agents. Metronidazole.

J E Rosenblatt1, R S Edson.   

Abstract

Metronidazole, a nitroimidazole derivative, is a unique antimicrobial agent that is active against both bacterial and parasitic organisms, although only the anaerobic members of these groups are susceptible. It has been used for the treatment of trichomoniasis for almost 30 years and is also effective in amebiasis and giardiasis. More recently, metronidazole has emerged as a principal agent for the treatment of anaerobic infections. It is highly effective against all species of anaerobes except certain non-spore-forming gram-positive bacilli and cocci and is the only agent rapidly bactericidal against the Bacteroides fragilis group. The hydroxy metabolite is 65% as effective as metronidazole and may play a major therapeutic role. Clinical studies have substantiated its efficacy for prophylaxis during elective colorectal surgical procedures and the treatment of deep abdominal sepsis (usually in combination with another agent such as an aminoglycoside). Metronidazole is the treatment of choice for bacterial vaginosis and seems to be as effective as vancomycin for treatment of Clostridium difficile-related diarrhea and colitis. Good blood levels are produced after both oral and intravenous administration, and side effects are infrequent and minimal. Metronidazole should not be taken during the first trimester of pregnancy because of concerns about mutagenicity. Tinidazole and ornidazole are recently developed nitroimidazole derivatives that have even greater antimicrobial activity than metronidazole.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3312851     DOI: 10.1016/s0025-6196(12)65074-5

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  7 in total

Review 1.  From Leningrad to the day-care center. The ubiquitous Giardia lamblia.

Authors:  W X Shandera
Journal:  West J Med       Date:  1990-08

2.  Plasma hydroxy-metronidazole/metronidazole ratio in patients with liver disease and in healthy volunteers.

Authors:  M N Muscará; J Pedrazzoli; E L Miranda; J G Ferraz; E Hofstätter; G Leite; A F Magalhães; S Leonardi; G De Nucci
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

3.  Single-dose ornidazole versus seven-day metronidazole therapy of giardiasis in Kibbutzim children in Israel.

Authors:  B Oren; E Schgurensky; M Ephros; I Tamir; R Raz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

4.  In vitro activities of metronidazole and its hydroxy metabolite against Bacteroides spp.

Authors:  S L Pendland; S C Piscitelli; P C Schreckenberger; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

5.  A comparative study of oral single dose of metronidazole, tinidazole, secnidazole and ornidazole in bacterial vaginosis.

Authors:  Jyoti Thulkar; Alka Kriplani; Nutan Agarwal
Journal:  Indian J Pharmacol       Date:  2012-03       Impact factor: 1.200

Review 6.  Metronidazole vaginal gel 0.75% (MetroGel-Vaginal): a brief review.

Authors:  A M Wain
Journal:  Infect Dis Obstet Gynecol       Date:  1998

7.  Randomized, double-blind, comparative study of oral metronidazole and tinidazole in treatment of bacterial vaginosis.

Authors:  Indu M Raja; Asha Basavareddy; Deepali Mukherjee; Bikash Ranjan Meher
Journal:  Indian J Pharmacol       Date:  2016 Nov-Dec       Impact factor: 1.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.